Day 1 | Tuesday 14 November

From 11:30 | REGISTRATION

12:00 – 13:00 | WELCOME LUNCH
A chance to meet fellow attendees and enjoy a light buffet lunch

13:00 – 13:10 | CONFERENCE WELCOME
Scientific Programme Committee

SESSION 1: TECHNOLOGIES AND GENOMICS
Chair: Sophie Postel-Vinay

13:10 – 13:45 | OPENING KEYNOTE LECTURE
Scott Lowe MSKCC, USA
"Understanding and exploiting tumor suppressive programs"

13:55 – 14:15 | Céline Vallot Institut Curie, France
"Mechanisms of cell plasticity in breast cancers"

14:25 – 14:35 | Mirja Rotinen Public University of Navarre, Spain
Proffered Paper 1: "ONECUT2 is a targetable lineage plasticity modulator of breast cancer that suppresses the estrogen axis"

14:40 – 14:50 | EXHIBITOR INTRODUCTIONS
60-second intro pitches by each company

14:50 – 15:20 | COFFEE BREAK & EXHIBITION

15:20 – 15:40 | Jean Soulier Hôpital Saint-Louis, INSERM, France
"Secondary leukemia to stressed hematopoiesis"

15:50 – 16:10 | Renata Basto Institut Curie, France
"Centrosome amplification induces apoptotic priming and favors the response to chemotherapy in epithelial ovarian cancer beyond multipolar divisions"
16:20 – 16:30 POSTER SPOTLIGHTS
*Posters 11, 17, & 25 will be presented in short 3-minute ‘flash talks’*

16:30 - 17:00 MEET THE EXPERT SESSION
*This informal and interactive session will be a great opportunity for participants to gain insight and advice from two of our outstanding speakers, Yves Pommier and Céline Vallot."

17:00 - 17:45 WELCOME RECEPTION with drinks and a light buffet

17:45 - 19:15 POSTER DISCUSSION SESSION 1
*Presenters of odd numbered posters should stand by their boards*

---

Day 2 | Wednesday 15 November

08:30 – 09:00 POSTER VIEWING

SESSION 2: LEUKEMIA THERAPY Chair: Patrick Mehlen

09:00 – 09:20 Q&A: 09:20 – 09:30
Andreas Trumpp DKFZ, Germany
"MAC-scoring in leukemic stem cells predicts response to Venetoclax in AML patients"

09:30 – 09:40 Q&A: 09:40 – 09:45
Irina Korovina HZDR, Germany
Proffered Paper 2: "Integrin α2-deficiency reduces treatment resistance in glioblastoma by modulating ATF1 activity"

09:45 – 10:05 Q&A: 10:05 – 10:15
Hugues de Thé College de France, France
"From nuclear architecture to leukemia cure: emerging roles of PML"

10:15 – 10:35 Q&A: 10:35 – 10:45
Yves Pommier NCI, USA
"Genomics and Schlafen 11 (SLFN11) as predictors in oncology clinical trials"

10:45 – 11:15 COFFEE BREAK & EXHIBITION

11:15 – 11:35 Q&A: 11:35 – 11:45
Julien Ablain CRCL, France
"Investigating the mechanisms of melanoma development and therapy response using zebrafish"

11:45 – 11:55 Q&A: 11:55 – 12:00
Laura Broutier CRCL, France
Proffered Paper 3: "Modelling the next-generation of fusion-negative rhabdomyosarcoma 3D-organoids to predict effective drug combinations: a proof-of-concept on cell death inducers"
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 – 12:10</td>
<td>POSTER SPOTLIGHTS</td>
<td><em>Posters 24, 36, &amp; 42 will be presented in short 3-minute ‘flash talks’</em></td>
</tr>
<tr>
<td>12:10 – 13:10</td>
<td>LUNCH &amp; EXHIBITION</td>
<td></td>
</tr>
<tr>
<td>13:10 – 14:40</td>
<td>POSTER DISCUSSION SESSION 2</td>
<td><em>Presenters of even numbered posters should stand by their boards</em></td>
</tr>
<tr>
<td>14:40 – 15:00</td>
<td>SESSION 3: NOVEL APPROACHES TO DRUG SENSITIVITY</td>
<td>Chair: Hugues de Thé</td>
</tr>
<tr>
<td></td>
<td>Sophie Postel-Vinay</td>
<td>IGR, France</td>
</tr>
<tr>
<td></td>
<td>Q&amp;A: 15:00 – 15:10</td>
<td>&quot;Harnessing genetic vulnerabilities in immuno-oncology: novel therapeutic opportunities&quot;</td>
</tr>
<tr>
<td>15:10 – 15:20</td>
<td>Mattia Marinucci</td>
<td>University of Basel, Switzerland</td>
</tr>
<tr>
<td>15:25 – 15:35</td>
<td>Hyunbin Huh</td>
<td>Yonsei, South Korea</td>
</tr>
<tr>
<td></td>
<td>Q&amp;A: 15:35 – 15:40</td>
<td>Proffered Paper 5: &quot;Reprogramming anchorage dependency by adherent-to-suspension transition promotes metastatic dissemination&quot;</td>
</tr>
<tr>
<td>15:40 – 16:00</td>
<td>Patrick Mehlen</td>
<td>CRCL, France</td>
</tr>
<tr>
<td></td>
<td>Q&amp;A: 16:00 – 16:10</td>
<td>&quot;Targeting netrin-1 in cancer: from mechanisms of cell death to patients&quot;</td>
</tr>
<tr>
<td>16:10 – 16:40</td>
<td>COFFEE BREAK &amp; EXHIBITION</td>
<td></td>
</tr>
<tr>
<td>16:40 – 17:00</td>
<td>Fanny Jaulin</td>
<td>Gustave Roussy, France</td>
</tr>
<tr>
<td></td>
<td>Q&amp;A: 17:00 – 17:10</td>
<td>&quot;Organoids as tools for functional precision medicine in advanced pancreatic cancer&quot;</td>
</tr>
<tr>
<td>17:10 – 17:30</td>
<td>THE EMBO KEYNOTE LECTURE</td>
<td>Cedric Blanpain</td>
</tr>
<tr>
<td></td>
<td>Q&amp;A: 17:30 – 17:40</td>
<td>&quot;Targeting EMT mediated resistance to therapy&quot;</td>
</tr>
<tr>
<td>17:40 – 18:40</td>
<td>PANEL DISCUSSION</td>
<td>Chair: Hugues de Thé</td>
</tr>
<tr>
<td></td>
<td>Sophie Postel-Vinay, Patrick Mehlen, &amp; Fanny Jaulin</td>
<td><em>This interactive session will provide a unique platform for attendees to exchange ideas and perspectives, to gain a comprehensive understanding of the evolving landscape of translational research on therapy responses, to connect for future collaborations.</em></td>
</tr>
<tr>
<td>19:30</td>
<td>OPTIONAL CONFERENCE DINNER</td>
<td>The 3-course dinner will be at the Hotel Crowne Plaza Lyon’s restaurant, Bistrot Rive Gauche. Optional ticketed event.</td>
</tr>
</tbody>
</table>
Day 3 | Thursday 16 November

08:30 – 09:00  POSTER VIEWING

SESSION 4: METABOLISM AND SENESCENCE
Chair: Sophie Postel-Vinay

09:00 - 09:20  Filipe Cabriero MRC London Institute of Medical Sciences, UK
Q&A: 09:20 – 09:30
"Microbially derived adjuvants for cancer chemotherapy"

09:30 – 09:50  Jean-Emmanuel Sarry Oncopole, France
Q&A: 09:50 – 10:00
"Metabolic bases of drug resistance in acute myeloid leukemia"

10:00 – 10:10  Rocio Matesanz Sanchez OncoRay, Germany
Q&A: 10:10 – 10:15
Proffered Paper 6: "Targeting exostosin glycosyltransferase 2 (EXT2) modulates glioblastoma cell metabolism, sensitizing to X-ray irradiation via ferroptosis"

10:15 – 10:45  COFFEE BREAK & EXHIBITION

10:45 – 11:05  Geraldine Gentric Institut Curie, France
Q&A: 11:05 – 11:15
"Role of stromal heterogeneity in resistance to treatments"

11:15 - 11:50  CLOSING KEYNOTE LECTURE
Clemens Schmitt Max Delbruck Center, Germany
Q&A: 11:50 – 12:00
"Apoptosis-competent anticancer treatment failure"

12:00  SUMMARY, AWARDS & DEPART
Travel Grants

More information about EACR grants: eacr.org/travel-grant

**EACR-Worldwide Cancer Research** Travel Grants provide funds to help early-career EACR members and researchers based in low- or middle-income economy countries to participate in our conferences.

Congratulations to the recipients of the Travel Grants for this conference. Each recipient received a full registration free of charge and funds to assist with travel and accommodation costs.

- **DAVID HACKETT** IRELAND
- **SAMEER KUMAR PANDA** ITALY
- **ANXO RÍO VILARIÑO** SPAIN
- **DANIELA SCHULZ** GERMANY
- **GIZEM YALÇIN** TURKEY

Supporters

We would like to thank the following grant providers:

This activity has been supported by a grant from F. Hoffman-La Roche Ltd, which has had no control over the educational content of this activity.

Our thanks also to the following partners for supporting us in promoting this conference:
## Meet the Exhibitors

<table>
<thead>
<tr>
<th>Exhibitor</th>
<th>Stand</th>
<th>Website</th>
<th>Represented at the conference by</th>
</tr>
</thead>
<tbody>
<tr>
<td>SB-PEPTIDE</td>
<td>1</td>
<td><a href="http://www.sb-peptide.com">www.sb-peptide.com</a></td>
<td>Aurélien Claeyssen</td>
</tr>
<tr>
<td>InSCREENex</td>
<td>2</td>
<td><a href="http://www.inscreenex.de">www.inscreenex.de</a></td>
<td>Tobias May, Kristina Nehlsen</td>
</tr>
<tr>
<td>MedChemExpress</td>
<td>3</td>
<td><a href="http://www.medchemexpress.com">www.medchemexpress.com</a></td>
<td>Inès Hoang, Myriam Loukrik, Johnny Truong</td>
</tr>
<tr>
<td>Don Whitley Scientific</td>
<td>4</td>
<td><a href="http://www.dwscientific.com">www.dwscientific.com</a></td>
<td>Alun Kitsell, Christophe Salgueiro</td>
</tr>
<tr>
<td>Cancer Research Centre of Lyon</td>
<td>5</td>
<td><a href="http://www.crcl.fr">www.crcl.fr</a></td>
<td>Quynh Chuong</td>
</tr>
<tr>
<td>VectorBuilder</td>
<td>6</td>
<td><a href="http://en.vectorbuilder.com">en.vectorbuilder.com</a></td>
<td>Gaetan Domin</td>
</tr>
<tr>
<td>Nonacus</td>
<td>7</td>
<td><a href="http://nonacus.com">nonacus.com</a></td>
<td>Elodie Desmaris</td>
</tr>
</tbody>
</table>
1 Molecular portrait of hormone therapy-resistant and sensitive breast cancer patients Presented by Suhail Ahmad, Advanced Centre for Treatment, Research and Education in Cancer & Homi Bhabha National Institute, Mumbai, INDIA

2 The anterior gradient homologue 2 (AGR2) co-localises with the glucose-regulated protein 78 (GRP78) in cancer stem cells, and is critical for the survival and drug resistance of recurrent glioblastoma: in situ and in vitro analyses Presented by Reem Alsereihi, Alayna Colleges, Madina & King Fahd Center for Medical Research, Jeddah, SAUDI ARABIA

3 Pancreatic stellate cell-induced gemcitabine resistance in pancreatic cancer is associated with enhanced glycolysis Presented by Manoj Amrutkar, Oslo University Hospital Rikshospitalet, NORWAY

4 Responses to cellular stress analyzed by quantitative phase microscopy Presented by Miguel Arocena, Universidad de la República, Montevideo, URUGUAY

5 PD-L1 Knockout Suppresses TNBC Cell Proliferation, Migration, Invasion, and Tumor Growth: Unveiling Therapeutic Opportunities through Signaling Pathway Analysis Presented by Samir Attoub, United Arab Emirates University, AI AIN, UNITED ARAB EMIRATES

6 Evaluation of Potential Anticarcinogenic Effects of Liposomal Prodrug SN38-Oleic Acid on Triple Negative Breast Cancer Cells Presented by Rümeysa Fatma Balaban, Uludag University, Bursa, TURKEY

7 Crosstalk between melanosomes and mitochondria: a new druggable interface for metastatic melanoma Presented by Caterina Baldanzi, CNR & CRL-ISPRO, Pisa, ITALY

8 Myxofibrosarcoma cell lines derived from primary tumor or recurrence show different sensitivity to photodynamic therapy Presented by Chiara Bellotti, IRCCS Istituto Ortopedico Rizzoli, Bologna, ITALY

9 Virotherapy for Triple-Negative Breast Cancer Presented by Olga Bezborodova, Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION

10 Mitochondrial metabolic alterations contributes to imatinib-resistance in chronic myeloid leukemia cell line Presented by Manish Bhat, ACTREC & Homi Bhabha National Institute, Mumbai, INDIA

11 [POSTER SPOTLIGHT] In-depth phosphoproteomics reveals novel mechanisms of tyrosine kinase inhibitor resistance in chronic myeloid leukemia Presented by Valeria Bica, University of Rome, ITALY

12 Next generation proteomics identifies a potential protein marker of poor response to tyrosine kinase inhibitors in metastatic renal cell carcinoma Presented by Pavla Bouchalova, Masaryk University, Brno, CZECH REPUBLIC
13 Combination of Remdesivir and Quercetin in TNBC Cells Regulates the EMT Pathway Presented by Ebrucan Bulut, Bursa Uludag University, TURKEY

14 Unleashing the Immune System Against Triple Negative Breast Cancer Through Inactivation of the Hsp90 Chaperoning Machine Presented by Ahmed Chadli, Georgia Cancer Center at Augusta University, Georgia, USA

15 p53 pathway reactivation selectively impairs viability of aggressive Ewing’s sarcoma stem-like cells Presented by Lucie Curylova, Masaryk University & International Clinical Research Center, St. Anne’s University Hospital, Brno, CZECH REPUBLIC

16 Innovative 3D models to characterise the interplay of integrins adhesion receptors and ion channels in the crosstalk between Pancreatic Ductal AdenoCarcinoma (PDAC) cell lines and Tumour MicroEnvironment (TME) Presented by Franco Nicolás D’Alessandro, University of Siena & University of Florence, ITALY

17 [POSTER SPOTLIGHT] A novel combinatorial therapy improves the outcome of infant t(4;11) pro-B-ALL by reverting epigenetic repression of HDAC7 biomarker Presented by Oriol de Barrios Barri, Josep Carreras Leukaemia Research Institute, Badalona, SPAIN

18 Targeting BRD9 as a Potential Therapy Approach for Glioblastoma Presented by Nareg Degirmenci, Koç University Research Center for Translational Medicine, Istanbul, TURKEY

19 Identification and validation of potent inducers of breast cancer stem cell differentiation Presented by Monica Fedele, IEOS, CNR, Naples, ITALY

20 Establishment of ex-vivo tissue culture model for preclinical hepatocellular carcinoma treatment and hepatotoxicity evaluation Presented by Huiche Feng, University Hospital Basel, SWITZERLAND

21 Harnessing mesenchymal stem cells-Mediated Tumor Microenvironment Perturbation for Enhanced Chemiosensitivity: proposing a preclinical study as a step towards clinical implementation of a promising hypothesis Presented by Benedetta Ferrara, IRCCS San Raffaele, Milano, ITALY

22 In vitro and in vivo characterization of the combinatorial effect of Axitinib and N-acetyl cysteine treatment in glioblastoma Presented by Alessia Formato, IBBC-CNR, Rome, ITALY

23 Screening of FDA-approved drug library with an oncolytic vesicular stomatitis virus identifies novel candidate combinatorial treatments for pancreatic cancer Presented by Valery Grdzelishvili, University of North Carolina at Charlotte, USA

24 [POSTER SPOTLIGHT] FAO-supported OxPhos leukemic stem cells are sensitive to cold Presented by Emmanuel Griessinger, Université Côte d’Azur, Nice, FRANCE & University of Groningen, NETHERLANDS

25 [POSTER SPOTLIGHT] A chemical suppressor screening in zebrafish identifies Wnt/-catenin pathway inhibitors improving anticancer drug response. Presented by Naoyuki Nishiya, Iwate Medical University, Shiwa-gun, JAPAN
26 Targeting the miR-31-ATOX1-drug trafficking axis to enhance chemosensitivity of pancreatic ductal adenocarcinoma. Presented by David Hackett, Trinity College Dublin, IRELAND

27 Frequent inactivation of tumor suppressor genes is associated with early acquired resistance to EGFR inhibitors in lung adenocarcinoma. Presented by Supriya Hait, ACTREC & Homi Bhabha National Institute, Mumbai, INDIA

28 Looking for roles beyond DNA repair for XPF and SLX4 proteins in cancer cells. Presented by Lars Petter Jordheim, CRCL, Lyon, FRANCE

29 Ex vivo modified extracellular vesicles as immune cell stimulators. Presented by Klaudia Kiel, Mossakowski Medical Research Insitute Polish Academy of Sciences, Warsaw, POLAND

30 Cyclosporin A inhibits prostate cancer growth through suppression of E2F8. Presented by Da young Lee, Seoul National University College of Medicine, SOUTH KOREA

31 Nutlin-3a-loaded ethosomes as a delivery system in vitro to target p53 in melanoma. Presented by Giada Lodi, University of Ferrara, ITALY

32 ANGPTL4: A critical regulator of the proinflammatory secretome of senescent cells and of cancer initiation. Presented by Gabriela Makulyte, Lyon University & Equipe Labellisée la Ligue Contre le Cancer, Lyon, FRANCE

33 Metastases of colorectal cancer deserve their own classification and tailored therapies. Presented by Emilie Mamessier, CRCM -Inserm U1068 & Institut Paoli Calmettes, Marseille, FRANCE

34 Retinoic acid and proteotoxic stress induce AML cell death overcoming stromal cell protection. Presented by Silvia Masciarelli, Sapienza University of Rome, ITALY

35 Deciphering Mutant p53-PIK3CA Nexus: Opportunities for Targeted Therapy in High-Grade Serous Ovarian Cancer. Presented by Megha Mehrotra, ACTREC & Homi Bhabha National Institute, Mumbai, INDIA


37 Mitochondrial trafficking from MSC to cancer cells in the tumor microenvironment (TME) regulating breast cancer drug resistance. Presented by Sameer Kumar Panda, University of Campania "Luigi Vanvitelli", Naples, ITALY & University of South Australia and SA Pathology, Adelaide, AUSTRALIA

38 AURKA Inhibition Restores Cetuximab Efficacy via YAP1/TAZ Suppression. Presented by Anxo Rio Vilariño, Instituto de Investigaciones Sanitarias Fundación Jiménez Diaz, Madrid, SPAIN

39 Intracellular PD-L1 trafficking and response to irradiation in head and neck cancer. Presented by Sophia Rohrmüller, University Hospital Regensburg, GERMANY
40 Asparagus officinalis L. aqueous extracts mediate cell cycle block and migration inhibition in breast cancer cells Presented by Arianna Romani, University of Ferrara & LTTA Centre, Ferrara, ITALY

41 The role of tumor-derived extracellular vesicles in modulating neutrophils towards a pro-tumor angiogenic state in head and neck squamous cell carcinoma Presented by Dominique Rubenich, Universidade Federal de Ciências da Saúde de Porto Alegre, BRAZIL & University Hospital Regensburg, GERMANY

42 [POSTER SPOTLIGHT] Understanding and exploiting chemotherapy metabolism – targeting the dNTP hydrolase SAMHD1 Presented by Sean Rudd, SciLifeLab & Karolinska Institutet, Stockholm, SWEDEN

43 Regorafenib in glioblastoma: in vitro characterization of tumor cells response Presented by Maria Salbini, IBBC-CNR, Rome, ITALY

44 PD-L1 in Head and Neck Cancer: Much more than just an immune regulatory protein Presented by Daniela Schulz, Department of Oral and Maxillofacial Surgery, Regensburg, GERMANY

45 Understanding CDK4/6 inhibitor resistance: The cell cycle position matters Presented by Xu Shen, University College London, UK

46 Ginsenoside compound K induces ferroptosis via Nur77 under hypoxic microenvironment Presented by Zeyu Shi, University of Hong Kong & Laboratory for Synthetic Chemistry and Chemical Biology Limited, Hong Kong, P.R. CHINA

47 Characterization of Non-Small Cell Lung Cancer (NSCLC) Akt2’s Molecular Changes Using an Air-Liquid (ALI) Culture Approach Presented by Carolina Sousa, University of Lisbon, PORTUGAL

48 Circular MALAT1 – the new kid on the block in breast-to-brain metastatic cancer Presented by Adrian Szczepaniak, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, POLAND

49 Mitochondrial DNA mutations in ovarian cancer and their impact on the response to anti-VEGF therapy in PDX models Presented by Chiara Trento, University of Padova, ITALY

50 Finding Therapy-Induced Vulnerabilities in Patient-Derived Organoids Established from Metastatic Colorectal Cancer via High-throughput-3D-Imaging of Drug Screening Presented by Gizem Yalçın, Middle East Technical University, Ankara, TURKEY

51 TELO2, a regulator of phosphatidylinositol 3-kinase-related kinases, is a druggable target for an inhibitor of the Wnt/-catenin and the mTOR signaling Presented by Honami Yonezawa, Iwate Medical University, Shiwa-gun, JAPAN

52 CONCEPT: a study for multiomic characterization of hepatobiliary cancers Presented by Michele Zanoni, IRCCS, IRST, Meldola, ITALY

53 Development of the first PROTACs targeting nuclear BRAFV600E in cancer Presented by Mourad Zerfaoui, Tulane University, New Orleans, USA

NOT A MEMBER YET? JOIN NOW

Apply for funding to develop your research & expand your horizons

Benefit from member registration rates at EACR events

Join our Science Book Club on LinkedIn

Build new connections with our ‘Find a Collaborator’ tool

Search the EACR Member Network and message other members

Share your perspective: write for The Cancer Researcher magazine

Access our free expert webinars on research & careers

Stay informed with regular updates on news, jobs & conferences

Volunteer for our Ambassador Programme or committees
EACR Conference: Cellular Bases for Patient Response to Cancer Therapies
Lyon, France | 14 - 16 November 2023

EACR on-site team

Hannah Barrs
Conference Officer

Kathryn Wass
Programmes Manager

Steph Milsom
Marketing Officer

Alexandra Boitor
Scientific Officer

Conference Dinner

Optional Ticketed Event: Wednesday 15 November, 19:30

The Conference Dinner will take place on the final night of the meeting. It will be an excellent opportunity for participants and speakers to get to know each other in a relaxed and informal environment.

The dinner is being held at the Hotel Crowne Plaza Lyon in their restaurant Bistrot Rive Gauche, located a short walk from the Centre de Congrès de Lyon.

Venue
Bistrot Rive Gauche
Crowne Plaza Lyon – Cite Interationale
22 Quai Charles de Gaulle
Lyon 69 006

Tickets for the conference dinner are not included in the registration fee.
EACR Industry Partners

The European Association for Cancer Research gratefully acknowledges its Industry Partners, who offer ongoing support to the EACR and provide the means for the Association to develop important initiatives.

[Image of logos of various companies]